235 related articles for article (PubMed ID: 30447924)
1. The role of Cancer/Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy.
Shires K; Van Wyk T
Crit Rev Oncol Hematol; 2018 Dec; 132():17-26. PubMed ID: 30447924
[TBL] [Abstract][Full Text] [Related]
2. Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy.
Gordeeva O
Semin Cancer Biol; 2018 Dec; 53():75-89. PubMed ID: 30171980
[TBL] [Abstract][Full Text] [Related]
3. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
4. Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.
de Carvalho F; Vettore AL; Colleoni GW
Clin Dev Immunol; 2012; 2012():257695. PubMed ID: 22481966
[TBL] [Abstract][Full Text] [Related]
5. Expression of Cancer-Testis Antigens in Pediatric Cancers.
Ghafouri-Fard S
Asian Pac J Cancer Prev; 2015; 16(13):5149-52. PubMed ID: 26225644
[TBL] [Abstract][Full Text] [Related]
6. [Reseach Advances on Cancer-Testis Antigens in Multiple Myeloma -Review].
Yang ZR; Yu L; Zhu HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):296-300. PubMed ID: 28245420
[TBL] [Abstract][Full Text] [Related]
7. Roles of cancer/testis antigens (CTAs) in breast cancer.
Li Y; Li J; Wang Y; Zhang Y; Chu J; Sun C; Fu Z; Huang Y; Zhang H; Yuan H; Yin Y
Cancer Lett; 2017 Jul; 399():64-73. PubMed ID: 28274891
[TBL] [Abstract][Full Text] [Related]
8. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.
van Duin M; Broyl A; de Knegt Y; Goldschmidt H; Richardson PG; Hop WC; van der Holt B; Joseph-Pietras D; Mulligan G; Neuwirth R; Sahota SS; Sonneveld P
Haematologica; 2011 Nov; 96(11):1662-9. PubMed ID: 21791470
[TBL] [Abstract][Full Text] [Related]
9. Melanoma: a prototype of cancer-testis antigen-expressing malignancies.
Faramarzi S; Ghafouri-Fard S
Immunotherapy; 2017 Oct; 9(13):1103-1113. PubMed ID: 29032737
[TBL] [Abstract][Full Text] [Related]
10. Expression of cancer-testis antigens in stem cells: is it a potential drawback or an advantage in cancer immunotherapy.
Ghafouri-Fard S
Asian Pac J Cancer Prev; 2015; 16(7):3079-81. PubMed ID: 25854409
[TBL] [Abstract][Full Text] [Related]
11. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.
Chiriva-Internati M; Cobos E; Kast WM
Int Rev Immunol; 2007; 26(3-4):197-222. PubMed ID: 17558744
[TBL] [Abstract][Full Text] [Related]
12. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.
de Carvalho F; Alves VL; Braga WM; Xavier CV; Colleoni GW
Cancer Immunol Immunother; 2013 Jan; 62(1):191-5. PubMed ID: 23180015
[TBL] [Abstract][Full Text] [Related]
13. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy.
Chiriva-Internati M; Mirandola L; Yu Y; Jenkins MR; Gornati R; Bernardini G; Gioia M; Chiaramonte R; Cannon MJ; Kast WM; Cobos E
J Immunother; 2011; 34(6):490-9. PubMed ID: 21654522
[TBL] [Abstract][Full Text] [Related]
14. Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application.
Wei R; Dean DC; Thanindratarn P; Hornicek FJ; Guo W; Duan Z
Cancer Lett; 2020 Jun; 479():54-60. PubMed ID: 31634526
[TBL] [Abstract][Full Text] [Related]
15. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma.
Seifi-Alan M; Shamsi R; Ghafouri-Fard S
Immunotherapy; 2018 Apr; 10(5):411-421. PubMed ID: 29473472
[TBL] [Abstract][Full Text] [Related]
16. Cancer-testis antigens: An update on their roles in cancer immunotherapy.
Taherian-Esfahani Z; Dashti S
Hum Antibodies; 2019; 27(3):171-183. PubMed ID: 30909205
[TBL] [Abstract][Full Text] [Related]
17. Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma?
Braga WM; da Silva BR; Alves VL; Bortoluzo AB; Atanackovic D; Colleoni GW
Immunotherapy; 2014; 6(5):569-75. PubMed ID: 24896625
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy strategies in multiple myeloma.
Bae J; Munshi NC; Anderson KC
Hematol Oncol Clin North Am; 2014 Oct; 28(5):927-43. PubMed ID: 25212890
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
20. Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy.
Andrade VC; Vettore AL; Panepucci RA; Almeida MS; Yamamoto M; De Carvalho F; Caballero OL; Zago MA; Colleoni GW
Leuk Lymphoma; 2010 Aug; 51(8):1543-9. PubMed ID: 20528248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
